Cost effectiveness of analysis of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: The Italian perspective;Cost-efficacia di irbesartan in paziente con diabete di tipo 2, ipertensione e nefropatia: Prospettiva Italiana

PharmacoEconomics - Italian Research Articles

Volumn 7, Issue 1, 2005, Pages 43-57

  Palmer, A J ^a   Annemans, L ^b,c   Roze, S ^a   Lamotte, M ^b   Berto, Patrizia ^d   Ravera, M ^e   Rodby, R A ^f  

^a IQVIA   (United States)

^b HEDM   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d Pbe Consulting   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; PLACEBO; VASODILATOR AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG COST; HUMAN; HYPERTENSION; INCIDENCE; ITALY; KIDNEY FAILURE; LIFE EXPECTANCY; LONG TERM CARE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROBABILITY; SENSITIVITY ANALYSIS; STANDARDIZATION; STATISTICAL MODEL; TREATMENT OUTCOME;

EID: 14844311240     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320534     Document Type: Article

References (47)

1. Bruno G, Cavallo-Perin P, Bargero G, et al. Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care 1996; 19 (1): 43-7
2. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34 (5): 795-808
3. Locatelli F, Pozzoni P, Del Vecchio L. Epidemiology of chronic kidney disease in Italy: possible therapeutical approaches. J Nephrol 2003; 16 (1): 1-10
4. Catalano C, Postorino M, Kelly PJ, et al. Diabetes mellitus and renal replacement therapy in Italy: prevalence, main characteristics and complications. Nephrol Dial Transplant 1990; 5 (9): 788-96
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
6. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322-38
7. Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25 (7): 2103-19
8. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003; 18: 2059-66
9. Lewis EJ, Hunsicke LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62
10. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996; 19 (10):1051-61
11. Garattini L, Brunetti M, Salvioni F, et al. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. PharmacoEconomics 1997; 12 (1): 67-75
12. Rodby RA, Rohde RD, Clarke WR, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000; 15 (4): 487-97
13. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134 (8): 629-36
14. Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19 (6): 1149-59
15. Leibson CL, O'Brien PC, Atkinson E, et al. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol 1997; 146 (1): 12-22
16. Registro Italiano Nazionale Dialisi e Trapianto. www.sin-ridt.org. 2001
17. Conte F, Limido A, Malberti F, et al. Registro Lombardo Dialisi e Trapianto (RLDT): 31 December 1997 update - Annual Report Regione Lombardia - Direzione Generale Sanità, Milano: 21 December 1998
18. GioFil. Il Portale dell'Informazione Sanitaria Farmaceutica. www.giofil.it. Accessed 22.09.2003
19. wwwfederfarma.it Accessed 22.09.2003
20. o 178 8 settembre 1997
21. o 150 14 settembre 1996
22. Tariffario Regione Lombardia Comune Vimercate settembre 2003
23. Lucioni C, Garancini MP, Massi-Benedetti M, et al. Il costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Pharmaco-Economics - Italian Research Articles 2000; 2 (1): 1-21
24. Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics. PharmacoEconomics 1995; 7 (1): 1-6
25. Capri S, Ceci A, Terranova L. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Information Journal 2001; 35 (1): 189-201
26. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276 (15): 1253-8
27. Detsky AS, Redelmeier DA. Measuring health outcomes - putting gains into perspective. N Engl J Med 1998; 339 (6): 402-4
28. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998; 339 (6): 380-6
29. Szende A, Mogyorosy Z, Muszbek N. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodological guidelines. Eur J Health Econom 2002; 3: 196-206
30. Herman WH, Shahinfar S, Carides GW, et al. Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation. Diabetes Care 2003; 26 (3): 683-7
31. Palmer AJ, Annemans L, Roze S, et al. Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension. Dtsch Med Wochenschr 2004; 129 (1-2): 13-18
32. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004
33. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001
34. Lacourciere Y, Nadeau A, Poirier L, et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993; 21 (6pt1): 786-94
35. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-S155
36. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8 (9): 876-83
37. Agardh CD, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10 (3): 185-192
38. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (4): 597-603
39. Gaede P, Vedel P, Parving H-H, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22
40. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57 (2): 590-600
41. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl 2: B54-B64
42. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 713-20
43. Schadlich PK, Brecht JG, Brunetti M, et al. Cost-effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. PharmacoEconomics 2001; 19 (5 Pt 1):497-512
44. Ruggenenti P, Pagano E, Tammuzzo L, et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001; 59 (1): 286-94
45. Hendry BM, Viberti GC, Hummel S, et al. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM 1997; 90 (4): 277-82
46. Clark WF, Churchill DN, Forwell L, et al. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy CMAJ 2000; 162 (2): 195-98
47. Le Pen C, Petitjean P, Levy P et al. Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy:a cost-benefit approach. Nephrologie 1996; 17 (6):321-6